A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC
In tumors, the multi drug resistance phenomenon may occur through the efflux of chemotherapeutic drugs out of cancer cells, impeding their accumulation, and eventually reducing their toxicity. This process is mediated by transporters overexpressed in the plasma membranes of tumor cells, among which...
Main Authors: | Maria Pia Adorni, Maricla Galetti, Silvia La Monica, Matteo Incerti, Alessandro Ruffoni, Lisa Elviri, Ilaria Zanotti, Bianca Papotti, Delia Cavallo, Roberta Alfieri, Pier Giorgio Petronini, Franco Bernini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/2/989 |
Similar Items
-
MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines
by: Eva-Maria Packeiser, et al.
Published: (2023-05-01) -
Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo
by: Li Yang, et al.
Published: (2018-05-01) -
Prenylflavonoid Isoxanthohumol Sensitizes MCF-7/ADR Cells to Doxorubicin Cytotoxicity via Acting as a Substrate of ABCB1
by: Ming Liu, et al.
Published: (2017-06-01) -
STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1
by: Zhaoqing Li, et al.
Published: (2021-07-01) -
Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
by: Fang Wang, et al.
Published: (2020-03-01)